

Reflections on the Clinical Implications of Glial Fibrillary Acidic Protein and Neuroglobin in Ischemic Stroke [Letter]

Jijun Cao, Wen Zhang 

Department of Laboratory Medicine, Taicang Hospital Affiliated to Soochow University, The First People's Hospital of Taicang, Jiangsu, People's Republic of China

Correspondence: Wen Zhang, Taicang Hospital Affiliated to Soochow University, The First People's Hospital of Taicang, No. 58, Changsheng South Road, Taicang, Suzhou, Jiangsu, People's Republic of China, Email zhangwenqazwsx@yeah.net

Dear editor

We recently read the article published in your journal regarding the expression of glial fibrillary acidic protein (GFAP) and neuroglobin (NGB) in patients with ischemic stroke.¹ The study's objectives are clear, the methodology rigorous, and the conclusions carry significant clinical implications. The authors have successfully explored the potential of these biomarkers in assessing post-stroke prognosis, providing valuable insights for clinicians. However, we believe that further research is needed to refine these findings.

First, we would like to address some limitations concerning the biomarker detection methods used. Specifically, the detection technologies may have issues related to sensitivity and specificity, which could impact the accuracy of the results. Additionally, variations in laboratory procedures and technical inconsistencies might affect the reproducibility of the experimental outcomes. Therefore, it is advisable for future studies to conduct more thorough validations of the selected detection techniques and to standardize laboratory operations rigorously to ensure the reliability of the results.

Second, the article does not adequately investigate the influence of different subgroups (such as gender and medical history) on the levels of GFAP and NGB. These subgroup factors could significantly affect the expression of the biomarkers and subsequently influence the prognosis of stroke patients. For instance, variations in baseline diseases or physiological changes among patients of different genders may lead to differential biomarker levels,² making it crucial to understand these discrepancies in clinical practice.

Third, the potential impact of environmental factors³ and genetic backgrounds⁴ on protein expression was not considered, which may result in a one-sided perspective. Factors such as lifestyle, dietary habits, and genetic predisposition could all influence the levels of GFAP and NGB. Therefore, future research should include these variables to provide a more comprehensive evaluation of these biomarkers across diverse populations.

Despite these limitations, the contributions of this study should not be overlooked. The authors have offered a profound analysis of biomarkers in stroke patients, pointing the way for future clinical applications.

Data Sharing Statement

No datasets were generated or analyzed during the current study.

Funding

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Disclosure

The author declares that have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this communication.

References

1. Pawluk H, Kołodziejska R, Grześk G, et al. Expression of acidic fibrillar protein and neuroglobin in thrombolytic patients in ischemic stroke. *Clin Interventions Aging*. 2024;19:1529–1543. doi:10.2147/CIA.S469624
2. Bernstein SR, Kelleher C, Khalil RA. Gender-based research underscores sex differences in biological processes, clinical disorders and pharmacological interventions. *Biochem Pharmacol*. 2023;215:115737. doi:10.1016/j.bcp.2023.115737
3. Galkin F, Kovalchuk O, Koldasbayeva D, Zhavoronkov A, Bischof E. Stress, diet, exercise: common environmental factors and their impact on epigenetic age. *Ageing Res Rev*. 2023;88:101956. doi:10.1016/j.arr.2023.101956
4. Rust R. Ischemic stroke-related gene expression profiles across species: a meta-analysis. *J Inflamm*. 2023;20(1):21. doi:10.1186/s12950-023-00346-x

Dove Medical Press encourages responsible, free and frank academic debate. The content of the Clinical Interventions in Aging 'letters to the editor' section does not necessarily represent the views of Dove Medical Press, its officers, agents, employees, related entities or the Clinical Interventions in Aging editors. While all reasonable steps have been taken to confirm the content of each letter, Dove Medical Press accepts no liability in respect of the content of any letter, nor is it responsible for the content and accuracy of any letter to the editor.

Clinical Interventions in Aging

Dovepress

Publish your work in this journal

Clinical Interventions in Aging is an international, peer-reviewed journal focusing on evidence-based reports on the value or lack thereof of treatments intended to prevent or delay the onset of maladaptive correlates of aging in human beings. This journal is indexed on PubMed Central, MedLine, CAS, Scopus and the Elsevier Bibliographic databases. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.

Submit your manuscript here: <https://www.dovepress.com/clinical-interventions-in-aging-journal>

<https://doi.org/10.2147/CIA.S498371>